Trials / Withdrawn
WithdrawnNCT06219733
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared with Imatinib Monotherapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- MedPacto, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
Detailed description
This is an open-label, multi-center, randomized controlled study to evaluate the safety and efficacy of vactosertib 200 mg BID in combination with imatinib versus imatinib alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vactosertib | 200 mg PO BID 5 days on / 2 days off |
| DRUG | Imatinib | Imatinib 400 mg PO QD daily |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2022-05-23
- Completion
- 2022-05-23
- First posted
- 2024-01-23
- Last updated
- 2024-12-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06219733. Inclusion in this directory is not an endorsement.